Deferred Tax Assets, Valuation Allowance in USD of Transcode Therapeutics, Inc. from Q4 2020 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Transcode Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2020 to Q4 2024.
  • Transcode Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $16.1M, a 27.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Transcode Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $16.1M +$3.47M +27.4% 31 Dec 2024 10-K 15 Apr 2025
Q4 2023 $12.7M +$5.51M +76.9% 31 Dec 2023 10-K 15 Apr 2025
Q4 2022 $7.16M +$5.14M +254% 31 Dec 2022 10-K 01 Apr 2024
Q4 2021 $2.02M +$1.58M +364% 31 Dec 2021 10-K 31 Mar 2023
Q4 2020 $435K 31 Dec 2020 10-K 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.